91 results about "Glidant" patented technology

The invention discloses granules of a composition containing rhizoma polygonati. The granules comprise the following components in percentage by weight: 30%-50% of composition dry paste powder, 38%-58% of a filling agent, 0.1%-20% of an adhesive and 0.1%-2% of a flow aid, the composition comprises rhizoma polygonati, fructus lycii, flos chrysanthemi and radix glehniae. Wherein the filling agent is dextrin; wherein the adhesive is maltodextrin or povidone; wherein the flow aid is colloidal silicon dioxide. According to the composition disclosed by the invention, proper auxiliary materials and an adding mode thereof are selected, so that the inherent properties of the original extract are improved, the extract is not easy to soften, the caking tendency caused by moisture absorption or heat absorption among particles is avoided, and the caking probability is reduced.

The invention relates to a doxepin hydrochloride tablet. The doxepin hydrochloride tablet is prepared from doxepin hydrochloride, polyethylene glycol 6000, a filling agent, a disintegrating agent, a flow aid and a lubricating agent. The preparation method comprises the following steps: heating and melting polyethylene glycol 6000, adding a doxepin hydrochloride raw material according to a prescription proportion, and uniformly stirring and mixing; and after complete melting, rapidly cooling and solidifying to form a solid dispersion. And after curing, drying in a drying oven, crushing and sieving. And uniformly mixing the crushed particles with the filler and the lubricant, and directly tabletting. The doxepin hydrochloride has high hygroscopicity, is unstable to damp and heat and easily generates a large amount of impurities under strong oxidation conditions, the doxepin hydrochloride is firstly prepared into a solid dispersion and then is directly compressed, so that the medicine is highly dispersed in a carrier material in the states of molecules, colloids, amorphous forms, microcrystals and the like, and the effect of wrapping the medicine is achieved by controlling the ratio of the medicine to the carrier. Direct contact between the medicine and air is avoided, so that the problems of hygroscopicity and instability of the medicine are solved, and the product stability is improved.

The invention discloses an aspirin enteric-coated micro-tablet capsule and a preparation method thereof. The micro-tablet core auxiliary materials of the enteric-coated micro-tablet capsule comprise an excipient, a disintegrating agent, a stabilizer, a flow aid and a lubricant. Tartaric acid is adopted as a stabilizer of aspirin, gel silicon dioxide is adopted as a flow aid, a moisture absorption agent and a swelling agent, and a direct powder tabletting method is adopted to prepare a micro-tablet core; the invention provides the aspirin enteric-coated micro-tablet capsule which is good in powder flowability, stable and easy to control in process, good in stability, uniform in dissolution and release characteristics, stable in blood concentration and high in bioavailability.

The invention provides a nicotine orally disintegrating tablet with a multi-layer composite sustained-release structure and a preparation method of the nicotine orally disintegrating tablet. The nicotine orally disintegrating tablet comprises an inner layer, a middle layer and an outer layer, wherein the middle layer and the outer layer sequentially coat the inner layer from inside to outside; the outer layer comprises nicotine, instant starch and a lubricant; the middle layer comprises nicotine, ethyl cellulose, polyethylene glycol and a flow aid; the inner layer comprises the following components: nicotine nanoparticles coated with chitosan and sodium tripolyphosphate, an oral microenvironment regulator and a filling agent. According to the nicotine orally disintegrating tablet provided by the invention, due to the gradient coating structure design of the inner layer, the middle layer and the outer layer, the multi-stage accurate release of nicotine, namely early-stage quick release, middle-stage stable release and later-stage slow release, is realized, the reactions of dizziness, vomiting and the like caused by excessive release of nicotine are avoided, and the use comfort is improved. Meanwhile, the pH value of the oral cavity is adjusted, micro-ecological balance of the oral cavity is maintained, the content of volatile sulfide in breath is reduced, and breath is refreshed.

The invention relates to the field of pharmaceutical preparations, and particularly discloses an amorphous-state tigorazan tablet and a preparation method thereof. The amorphous-state tigorazan tablet comprises a tablet and a coating material in a weight ratio of 100: (2-4), the tablet comprises the following raw materials: amorphous-state tigorazan, a carrier inclusion material, an excipient, a disintegrating agent, a lubricant and a flow aid, the dosage of the amorphous-state tigorazan is 20-30% of the total mass of all the raw materials of the tablet, and the dosage of the carrier inclusion material is 20-30% of the total mass of all the raw materials of the tablet. The weight ratio of the amorphous tigoran to the carrier inclusion material is 1: (0.80-1.15), and the carrier inclusion material is vitamin E polyethylene glycol succinate. The amorphous tigorazan tablet provided by the invention not only has higher solubility and dissolution rate, but also has higher stability and better hardness and friability, not only improves the bioavailability of drugs, but also avoids the use of organic solvents, simplifies the production process, reduces the risks of production safety and environmental protection, and is suitable for large-scale industrial production.

The invention discloses an eperisone hydrochloride solid tablet composition and a preparation method thereof, the solid tablet composition contains eperisone hydrochloride, a filler, a disintegrating agent, an adhesive, a flow aid, a lubricant and a coating agent, and the preparation method comprises the following steps: preparing an adhesive aqueous solution; carrying out wet granule preparation, fluidized drying and granule finishing on the internally added materials in a fluidized drying granulator by using the adhesive solution, and mixing, tabletting and coating dry granules with a flow aid and a lubricant; the acidic disintegrating agent is introduced, so that the increase of related substances of the finished product under high temperature, high temperature and high humidity can be remarkably reduced; a fluidized bed is adopted for one-step granulation, and the prepared finished product has good dissolution rate and stability equivalent to that of a reference preparation; the eperisone hydrochloride tablet provided by the invention is stable in quality, simple and feasible in production process, high in controllability and easy for industrial production.

The invention discloses a tacrolimus-containing pellet pharmaceutical composition, the pharmaceutical composition is composed of an enteric pellet and a sustained-release pellet, the enteric pellet comprises 0.5-5% of tacrolimus, 10-80% of a filler, 2-10% of a disintegrating agent, 1-5% of an adhesive, 0.5-2% of a flow aid, 0.5-1% of a lubricant, and 5-13% of an enteric coating material; the sustained-release pellet comprises 0.5 to 2% of tacrolimus, 10 to 80% of a filling agent, 2 to 10% of a disintegrating agent, 1 to 5% of an adhesive, 0.1 to 1% of a flow aid, 0.1 to 1% of a lubricant, 5 to 15% of a sustained-release coating material and 0.1 to 0.5% of a plasticizer. The pellet pharmaceutical composition containing tacrolimus disclosed by the invention can maintain longer blood concentration and longer action time, so that the medicine taking frequency is reduced, the compliance of a patient is improved, the toxic and side effects are reduced, and the effectiveness and safety of medicine use are further ensured.

The present application belongs to the technical field of oral solid preparation, and particularly relates to a mosapride citrate orally disintegrating tablet and a preparation method thereof. Raw and auxiliary materials comprise mosapride citrate, a filling agent, a disintegrating agent, a glidant, a lubricant and a flavoring agent. The present application screens and optimizes the auxiliary material formula, adopts dry granulation, optimizes the preparation process, improves the compressibility and fluidity of the material, saves energy, improves the production quality and stability, makes the prepared orally disintegrating tablet disintegrate rapidly, has excellent taste, greatly improves the medication compliance of patients, simultaneously improves the drug dissolution and improves the bioavailability. In addition, compared with other types of solid oral preparations of the product, the mosapride citrate orally disintegrating tablet is particularly suitable for the elderly and patients with difficulty in swallowing, and provides convenience in special and urgent situations such as lack of drinking water for taking medicine.

The invention discloses a high-filling high-toughness PP (polypropylene) flame-retardant material and a preparation method thereof, and the high-filling high-toughness PP flame-retardant material comprises the following raw materials in percentage by weight: 45-52% of modified bamboo powder; the total proportion of the PP and the PP-g-MAH is 15%-20%, and the weight ratio of the block copolymerized PP to the PP-g-MAH is (1: 0.5)-(1: 1.5); the proportion of the POE-g-MAH is 10% to 22%; the proportion of the flame retardant is 12.5 to 14.5 percent; the proportion of the antioxidant is 0.4%-0.5%; synergistic and efficient reinforcing and toughening of the high-filling material are achieved, the small-amount and efficient result reserves enough space for increasing the proportion of the flame retardant in a blending system, and therefore high flame retardance of the material is achieved.

The present invention relates to an orodispersible tablet manufactured by a wet granulation method comprising pregabalin or pharmaceutically acceptable salts thereof, at least one disintegrant, at least one diluent, at least one binder, at least one glidant, at least one lubricant, and one or more pharmaceutically acceptable excipients. The orodispersible tablet prepared using these excipients exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. Further, the present invention also relates to the process for preparing the said solid pharmaceutical composition.

The invention provides a pharmaceutical composition which comprises a compound shown as a formula I or pharmaceutically acceptable salt and auxiliary materials, the auxiliary materials comprise one or more of a filling agent, an adhesive, a flow aid, a disintegrating agent and a lubricating agent, and the pharmaceutical composition has the advantages of preparation process preparation feasibility, excellent preparation properties, good stability and good dissolution performance and meets the medicinal standard.

The present invention relates to an orodispersible tablet manufactured by a direct compression method comprising Topiramate or pharmaceutically acceptable salts thereof, at least one or more diluents, at least two or more disintegrant, at least one lubricant, at least one glidant, and at least one flavoring agents. The orodispersible tablet prepared using these excipients exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. Further, the present invention also relates to the process for preparing the said Orodispersible tablet.

A pharmaceutical composition containing minoxidil, which is composed of minoxidil, a filler, a sustained-release material, a glidant and a lubricant, wherein the specification of minoxidil is 1.25-5.0 mg, and the sustained-release material is selected from hypromellose. The minoxidil composition has a sustained-release effect of 8-12 hours in vitro, has an ideal in-vivo plasma concentration and bioavailability, and ensures the safety and effectiveness of the use of minoxidil.

The invention discloses a pharmaceutical composition containing meclofenoxate hydrochloride, which is characterized by comprising meclofenoxate hydrochloride, a filling agent, a flow aid, a lubricant, a stabilizer and an antioxidant, the mass ratio of meclofenoxate hydrochloride to the stabilizer to the antioxidant is 1: (0.005-0.015): (0.001-0.005), the mass ratio of meclofenoxate hydrochloride to the filling agent to the flow aid is 1: (0.3-0.7): (0.1-0.5), and the lubricant is a lubricant. The stabilizer is benzoic acid. Benzoic acid is selected as a stabilizing agent, and the hygroscopicity is obviously lower than that of citric acid, in RHlt; and when the content is 80%, moisture is not absorbed basically, so that the meclofenoxate hydrochloride is effectively prevented from being hydrolyzed due to moisture absorption.

The present invention provides a composition of nebivolol and amlodipine, comprising nebivolol, amlodipine and a pharmaceutical excipient. The nebivolol comprises one or more of nebivolol, a pharmaceutically acceptable salt thereof, and a solvate thereof. The amlodipine comprises one or more of amlodipine, a pharmaceutically acceptable salt thereof, and a solvate thereof. The pharmaceutical excipient is selected from one or more of a filler, a binder, a disintegrant, a lubricant, and a glidant. The composition does not contain a colorant and a film coating. The compound preparation of the present invention has good stability, and is beneficial to improving the antihypertensive efficacy, enhancing safety and tolerability, and reducing side effects. Compared to monotherapy, the present invention reduces the number of administered medications and improves the compliance of patients, is beneficial to improving the medication compliance of the elderly patients and individuals with dysphagia, maintains a stable plasma drug concentration, maintains long-term stable blood pressure in hypertensive patients, prevents the patients from discontinuing medication arbitrarily, and prevents disease recurrence and the progression of severe complications.

A pharmaceutical composition, and a preparation method therefor and the use thereof. The pharmaceutical composition contains: (4aR,8R)-3-acryloyl-11-chloro-10-(2-fluoro-6-hydroxyphenyl)-8-(2-isopropyl-4-methylpyridin-3-yl)-6-methyl-2,3,4,4a,6,8-hexahydro-1H-pyrazino[1′,2′:4,5]pyrazino[2,3-c][1,8]naphthyridin-5,7-dione or a pharmaceutically acceptable salt thereof as an active ingredient; and one or more selected from a filler, a disintegrant, a lubricant, a glidant and a binder. The pharmaceutical composition has good stability and drug dissolution, and the preparation process is simple and is suitable for industrial production.

The application belongs to the technical field of pharmaceutical preparations, and particularly relates to a roxithromycin preparation and a preparation method thereof. The roxithromycin preparation is prepared from the following raw materials: roxithromycin, a stabilizer, a glidant, a filler, a binder and a lubricant. The stabilizer is a mixture of hydroxypropyl methyl cellulose and povidone. The glidant is talc. The stabilizer system used in the traditional high-pressure homogenization technology (HPH) is optimized according to the particularity of the roxithromycin raw material. The hydroxypropyl methyl cellulose and the povidone are used together, and the talc is introduced to improve the powder properties of the prepared nanocrystals, so that the subsequent production and manufacturing are facilitated. The preparation prepared according to the method has stable drug quality and accurate dosage.

The application belongs to the technical field of medicine, and particularly relates to a kind of opicapone oral disintegrating tablets and a preparation method thereof.The active component of the opicapone oral disintegrating tablet is opicapone, and the components are as follows according to weight percentage: opicapone 15-25%; filler 60-70%; glidant 1-4%; lubricant 1-4%; first disintegrating agent 2-6%; and second disintegrating agent 2-6%, wherein the first disintegrating agent and the second disintegrating agent are different, and preferably, the weight content of the opicapone is 15-20%.The opicapone oral disintegrating tablet of the application is suitable for the adjuvant therapy of levodopa / carbidopa, has a fast disintegration rate, stable product quality, does not need to be taken with water, and has strong patient compliance; in addition, the preparation process of the opicapone oral disintegrating tablet of the application is simple, has low cost, and is suitable for mass production.

The invention relates to a furosemide tablet and a preparation method thereof.The furosemide tablet is prepared from, by weight, 25.00% of furosemide, 40%-45% of filler, 27%-33% of adhesive, 0.5%-1.5% of lubricant, 1.0%-2.0% of anti-sticking agent and 0.5%-1.5% of flow agent.The furosemide tablet is prepared by adopting the technology that purified water is directly added without preparing the adhesive; a wet granulation process is adopted, the controllability of process parameters in the production process is high, the human influence of operation of multiple process steps is reduced, the quality stability of the medicine is effectively improved, the quality of the medicine is equivalent to that of a commercially available reference preparation, and multiple dissolution curves are similar to that of the reference preparation; the in-vitro dissolution behavior similar to that of a reference preparation is shown, the quality is stable, and the dissolution behaviors among batches are consistent.

This invention belongs to the field of silver catalysts, and relates to an α-alumina support, its preparation method, and silver catalysts and their applications. The preparation method of the α-alumina support includes the following steps: at least one of α-Al₂O₃ and α-Al₂O₃ trihydrate is mixed uniformly with pseudo-Al₂O₃ to obtain a solid mixture; this mixture is then wet-milled with deionized water in a ball mill to obtain a slurry; the resulting slurry is spray-granulated to obtain solid microsphere powder; the solid microsphere powder is mixed uniformly with a binder, flow aid, lubricant, and pore-forming agent to obtain pressed granules; the pressed granules are dry-pressed to obtain a molded body, which is then calcined to obtain the α-alumina support. The support obtained by this invention has a more controllable shape, and when used for the oxidation of ethylene to ethylene oxide, its selectivity and stability are significantly improved while maintaining activity.

The invention discloses an estradiol valerate film-coated tablet and a preparation method thereof. The estradiol valerate film-coated tablet comprises the following components in parts by weight: 1 part of estradiol valerate, 60-80 parts of a filler, 10-25 parts of a disintegrating agent, 5-12 parts of an adhesive, 1-3 parts of a flow aid, 1-3 parts of a lubricant and 8-14 parts of a film coating premix, and the filling agent is anhydrous lactose. After a sugar coating is changed into a film coating, the front end of the preparation is obviously and quickly dissolved out and is not similar to the original sugar-coated tablet, the tablet core is disintegrated in a corrosion manner by adjusting the dosage of lactose in the prescription, and the whole dissolution of the tablet is similar to the dissolution of the original sugar-coated tablet by adjusting the weight increment of the film coating. The process is simple, industrial production is facilitated, and the stability of the preparation is obviously improved.

The present application relates to a kind of upatin sustained-release tablets and preparation method thereof.The present application uses mannitol, microcrystalline cellulose as filler, hydroxypropyl methyl cellulose as matrix material, malic acid as pH regulator, colloidal silicon dioxide as glidant, magnesium stearate as lubricant, after mixing raw drug with one or more excipients, dry granulation, solve the upatin preparation in the tabletting process due to the hygroscopicity of pH regulator and cause the problem of astringent, sticky and product quality change, shorten the drying time of moisture control in coating process, tablet is more stable in the process of acceleration test and influencing factor test.

The present invention provides a pharmaceutical composition comprising ticagrelor at a dose of 90 mg, acetylsalicylic acid at a dose of from 75 to 100 mg, at least one of a diluent, a binder, a wetting agent, a glidant, and a lubricant. The pharmaceutical composition of the present invention solves a set of significant technological challenges due to the physicochemical properties and difference in dosage of each drug. Said pharmaceutical composition is stable, such that the composition is safe and effective in the treatment and prevention of cardiovascular diseases. The invention is further directed to a process for manufacturing a pharmaceutical composition.

The present invention provides terbinafine hydrochloride tablets, comprising terbinafine hydrochloride, a disintegrant, a binder, a polymethacrylic acid resin, glycolic acid, a glidant, and a lubricant. Compared with the prior art, the present invention uses glycolic acid, an organic acid, as a pH regulator to maintain an acidic pH environment throughout the tablet, thereby ensuring product stability throughout its storage cycle. Furthermore, polymethacrylic acid resin is used as a filler to improve the compressibility of the material, ensuring that the product meets hardness requirements throughout its storage cycle, with quality comparable to that of a tablet at day 0.

The invention discloses a blonanserin orally disintegrating tablet composition and a preparation method thereof, and relates to the technical field of preparations. The preparation method of the blonanserin orally disintegrating tablet composition comprises the following steps: uniformly mixing 60-100 parts of a diluent, 10-30 parts of a disintegrating agent, 0.5-2 parts of an adhesive, 1-3 parts of a flow aid and 1-5 parts of a sweetening agent to obtain a first mixture; 4 parts of blonanserin micro powder and 0.5-1.5 parts of a solubilizer are subjected to high-speed shearing emulsification with water for 5-15 min, and a second mixture is obtained; performing wet granulation on the second mixture, adding the second mixture into the first mixture, drying, adding 0.5-5 parts of a lubricant, mixing, and tabletting to obtain the blonanserin orally disintegrating tablet composition. According to the preparation method disclosed by the invention, the content uniformity, the dissolution rate and the dissolution rate of the blonanserin orally disintegrating tablet are improved, the disintegrating time limit of the tablet is within 1min, and the blonanserin orally disintegrating tablet is fragrant and sweet in smell and free from gravel feeling.

The present disclosure relates to oral dosage forms of pharmaceutical formulations that comprise an antiviral nucleoside, one or more compression aids, one or more glidants, and one or more lubricants, and one or more disintegrants, wherein the oral dosage form is a pellet having a diameter of less than or equal to 4.0 mm.

The invention discloses an atavalopag maleate tablet and a preparation method thereof. The atavalopag maleate tablet is prepared from the following components in percentage by weight: 12 to 15 percent of atavalopag maleate, 30 to 45 percent of modified beta-cyclodextrin, 3 to 4 percent of disintegrating agent, 0.5 to 1 percent of flow aid, 0.5 to 2 percent of lubricating agent and the balance of filling agent. The invention also provides a preparation method of the composition. According to the invention, the specific surface area of the medicine is increased by accurately controlling the particle size of the raw materials and clathrating the medicine, so that the medicine can be quickly dissolved in a dissolution medium, and the dissolution rate and the dissolution amount of the medicine are improved, thereby being beneficial to the absorption of the medicine in vivo, being beneficial to improving the bioavailability of the medicine and enhancing the treatment effect of the medicine.

The present invention relates to a pharmaceutical composition comprising a fixed dose combination of (a) netupitant, or a salt or hydrate thereof, and (b) palonosetron, or a salt or hydrate thereof, in a single pharmaceutical unit. The invention further relates to a method for preparing a pharmaceutical composition in the form of a tablet, the method comprises: (i) wet granulating a dry mixture comprising netupitant or a salt or hydrate thereof, a filler, a binder, a disintegrant, and optionally a surfactant and / or a lubricant, with a solution comprising palonosetron or a salt or hydrate thereof, and optionally a surfactant and / or a binder, to produce granules; (ii) blending the particles with a lubricant, a disintegrant and a glidant, and optionally a filler, and (iii) compacting the lubricated particles to produce a tablet. The invention further relates to the use of said pharmaceutical composition for the treatment and / or prevention of nausea and / or vomiting, preferably for the treatment and / or prevention of acute or delayed nausea and vomiting associated with chemotherapy, such as highly or moderately emetically induced cancer chemotherapy, such as cis-platinum cancer chemotherapy.

The invention discloses an abelsilib tablet and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The abesilib tablet comprises abesilib, a filling agent, a disintegrating agent, an adhesive, a flow aid, a lubricating agent and stabilizing agents sabolixa sodium and glycine. The preparation method of the abelsiil tablet comprises the steps of pretreatment, stabilizer treatment, granulation, drying, size stabilization, total mixing, tabletting, coating and the like. According to the present invention, through the synergistic stabilization effect of the sabolixabate sodium and the glycine and the optimized preparation process, the stability of the abesillitic tablet is improved, the process is simple and controllable, the cost is low, the product quality uniformity is good, the abesillitic tablet is suitable for large-scale production, and the reliable oral preparation selection is provided for breast cancer treatment.

The present application provides a kind of ticagrelor pharmaceutical composition, the composition includes ticagrelor and pharmaceutically acceptable carrier, the weight percentage of the ticagrelor is 10%-20%, the pharmaceutically acceptable carrier is selected from any one or combination of binder, disintegrant, diluent, lubricant, glidant, the weight percentage of the disintegrant is 10%-30%.The present application significantly reduces the dynamic disintegration time and static disintegration time of tablet by scientific screening and optimization of the formulation of solid pharmaceutical composition, facilitate the rapid absorption of drug in patients, avoid intubation simplify clinical medication regimen, in addition, it is convenient for patients with dysphagia to take medicine, significantly improve the compliance of patients to take medicine, optimize the particle size and particle powder properties of ticagrelor, solve the problem of large tablet weight difference and poor content uniformity caused by poor flowability of ticagrelor after tabletting, improve the uniformity, effectiveness and safety of the drug, realize the controllable quality of drug.